My Watchlist

Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

Can Pharmacyclics Turn It Around?

By | More Articles
October 1, 2012 | Comments (3)

Today, fool.com health-care analysts Brenton Flynn and David Williamson examine Pharmacyclics' September drop and look to explain the move. The company saw a huge run-up in August that raises the stakes for success. David cautions that a slip-up will send shares spiraling, as the company still doesn't have its potentially blockbuster drug in phase 3 trials at this time. 

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Brenton Flynn and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 03, 2012, at 11:42 PM, malibusunsetter wrote:

    WHat on earth is this article about? Not in phase III - can the authors not read? They are near their 52 week high as of today. Ever heard of profit taking? Myeloma results to be presented at ASH? You think they will publish poor results?

  • Report this Comment On October 04, 2012, at 9:35 AM, malibusunsetter wrote:

    Three phase III trials for Ibrutinib.

  • Report this Comment On October 04, 2012, at 1:36 PM, NVR2LATE4 wrote:

    Did someone just hire a seeking alpha writer? I read through this story, the entire time thinking, Do the have the right ticker symbol?

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 2039390, ~/Articles/ArticleHandler.aspx, 5/21/2013 8:25:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 15,335.28 -19.12 -0.12%
S&P 500 1,666.29 -1.18 -0.07%
NASD 3,496.43 -2.54 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/20/2013 4:00 PM
PCYC $81.86 Down -3.03 -3.57%
PHARMACYCLICS, INC… CAPS Rating: *
JNJ $88.01 Down -0.08 -0.09%
Johnson & Johnson CAPS Rating: *****

Advertisement